Urinary Bladder
Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate?
Duquesne I, et al
A narrative review of the four major NMIBC risk classification systems — AFU, EAU, AUA/SUO, and NCCN — concludes that current frameworks remain necessary but are no longer sufficient alone to guide treatment selection in an era of rapidly expanding therapeutic options. The four systems produce disco…
Source →Solid tumours in RASopathies: insights from a large monocentric cohort and systematic review of the literature.
Trevisan V, et al
A large monocentric cohort study and systematic literature review found that solid tumour risk in RASopathies is strongly syndrome-dependent, with Costello syndrome (CS) carrying the highest burden: 47.8% of CS individuals developed at least one solid tumour and 30.4% developed malignant tumours, pr…
Source →Quality of life in patients on active surveillance for bladder cancer.
Hurle R, et al
Patients with bladder cancer managed through active surveillance experience measurable impacts on health-related quality of life, underscoring the importance of patient-reported outcomes in this growing management strategy. The study, published in BJU International, evaluated quality-of-life metrics…
Source →Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck.
Mercader C, et al
A prospective study of 63 patients with indeterminate urinary cytology and negative cystoscopy found that the Bladder EpiCheck (BE) epigenetic urine test detected urothelial carcinoma (UC) with significantly higher sensitivity than repeated urinary cytology (80% vs. 17%, p < .001), while repeated cy…
Source →Predictive Biomarkers in Cancer Immunotherapy for Genitourinary Malignancies.
Paulet A, et al
A new review published in Critical Reviews in Oncology/Hematology synthesizes current and emerging predictive biomarkers for immune checkpoint inhibitor therapy across genitourinary cancers, with urothelial carcinoma — including bladder cancer — as a central focus. The authors evaluate established m…
Source →Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer.
Nössing C, et al
A new study published in European Urology Oncology reveals that gemcitabine-cisplatin (GC) chemotherapy causes downregulation of Nectin-4 — the molecular target of the antibody-drug conjugate enfortumab vedotin (EV) — in bladder cancer cells, leading to cross-resistance against EV in the post-platin…
Source →Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma.
Kawasaki JA, et al
A new study found that the BCL-2 gene variant rs2279115 is significantly associated with BCL-2 protein expression in urothelial bladder carcinoma, with the TT genotype (p = 0.035) and GT genotype (p = 0.045) linked to positive protein status. Furthermore, the CT haplotype — formed by combining the r…
Source →PRDX1 facilitates USP7-dependent stabilization of SCD1 and promotes bladder cancer progression.
Wang L, et al
A new study published in Cellular Signalling demonstrates that the antioxidant protein PRDX1 drives bladder cancer progression by stabilizing the lipid-desaturase enzyme SCD1 through the deubiquitinase USP7, which removes K48-linked polyubiquitin chains from SCD1 to prevent its proteasomal degradati…
Source →Cxbladder Triage in Haematuria Assessment Reduces Time From Referral to Specialist Assessment and Bladder Cancer Treatment and Improves Equity for Māori.
Eaton D, et al
Introducing the CxBladder Triage (CxBT) urine biomarker test into the primary care haematuria pathway in Canterbury, New Zealand, reduced waiting time from referral to urological specialist review by 14.8 days and time to first surgical treatment for bladder cancer by 15.0 days. This retrospective a…
Source →Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence
Gakis G, et al
A critical review of three phase III trials found that adding immune checkpoint inhibitors to a full 2-year BCG maintenance schedule significantly reduced recurrence in high-risk non-muscle-invasive bladder cancer (NMIBC), with the CREST (sasanlimab) and POTOMAC (durvalumab) trials each achieving a …
Source →A bladder matter: redefining the grading system for pediatric hemorrhagic cystitis.
Robey CL, et al
A retrospective study of 93 pediatric patients with hemorrhagic cystitis found that a bladder clot volume of ≥10% of estimated bladder capacity was the single strongest predictor of surgical intervention, with an odds ratio of 34.8 (p < 0.0001), while additional significant risk factors included mal…
Source →Intraoperative indocyanine green fluorescence guidance to reduce ureteroenteric anastomotic strictures during robot-assisted radical cystectomy. A systematic review and meta-analysis.
Nominato EO, et al
A systematic review and meta-analysis of four observational studies enrolling 886 patients (1,739 ureters) found no statistically significant reduction in ureteroenteric anastomotic strictures with indocyanine green (ICG) fluorescence guidance during robot-assisted radical cystectomy, yielding a poo…
Source →International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer: Working Group 2: The Urinary Bladder.
Downes MR, et al
An international expert consensus convened by the International Society of Urological Pathology (ISUP) in Vienna in September 2025 achieved agreement on 18 of 19 polling statements regarding standardized pathological evaluation of treatment effects in urinary bladder cancer, with only the use of mol…
Source →Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.
Maeda S, et al
A clinical study of 43 dogs with naturally occurring muscle-invasive urothelial carcinoma treated with first-line sorafenib and piroxicam achieved an overall response rate of 62.8%, with median progression-free and overall survival of 175 days (range 31–665) and 407 days (range 103–1,723), respectiv…
Source →Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
Odagiri K, et al
A retrospective study of 116 patients with metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV) identified eosinophil proportion as the only candidate biomarker for adverse events (AEs) of any grade, with a cutoff value of 2.5% yielding an area under the curve of 0.625. Patient…
Source →